Health News Digest: Exorcism Allegation, FDA Approvals, and Outbreak Alerts
A licensed practical nurse in Pennsylvania is accused of performing an exorcism on a nursing home resident. The FDA approved new treatments for a rare genetic disorder and a brain cancer diagnostic, while a Legionella outbreak in New York has affected nine people. Additionally, a woman died after an eight-hour plastic surgery session in Brazil, and Arizona sued L'Oreal over hair relaxer cancer risks.
The FDA expanded approval of leniolibis (Joenja) to treat activated phosphoinositide 3-kinase delta syndrome in children aged 4 to 11, a rare genetic disorder. The agency also approved floretyrosine F 18 (Pixclara), a radioactive diagnostic drug from Telix, to help distinguish glioma progression or recurrence from treatment-related changes.
A Legionella outbreak in New York City has sickened nine people, including one death, with a Yankees Stadium cooling tower testing positive. Separately, Arizona's attorney general sued L'Oreal, alleging the company concealed evidence linking hair relaxers to gynecologic cancer risks.
These developments could reshape public trust in several institutions. FDA approvals for rare disease treatments may offer new hope to affected families, while the Legionella outbreak underscores aging infrastructure risks in urban settings. The L'Oreal lawsuit could prompt broader scrutiny of cosmetic products and their long-term health effects. The exorcism allegation may heighten concerns about nursing home oversight and resident protection, potentially influencing regulatory reforms in elder care.